MADISON, Wis.—Quincy Bioscience announced it received a capital infusion from DaneVest Tech Fund I, a Madison-based investment group that specializes in privately held technology companies. Quincy Bioscience plans to use the funding to expand sales of its Prevagen® brain health dietary supplement.
“We are pleased to announce the partnership of DaneVest Tech Fund," said Michael J. Beaman, CEO at Quincy Bioscience. “2010 has been a banner year for Quincy Bioscience in terms of intellectual property development, research results on Prevagen’s active ingredient apoaequorin, and Prevagen sales growth. This investment will accelerate our goal to make Prevagen a national brand."
Prevagen was originally launched as a dietary supplement in 2007. Apoaequorin, the active compound, is a calcium-binding protein that helps protect neurons from the damaging effects of excess calcium. Studies have shown it can improve cognitive performance in older adults with memory concerns.
